AusperBio Announces IND Approval from China CDE for HBV ASO AHB-137

SAN FRANCISCO, June 28, 2023 /PRNewswire/ — AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of…

Click here to view original post